Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Identifieur interne : 000A84 ( Pmc/Curation ); précédent : 000A83; suivant : 000A85Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Auteurs : Yuan Zhuang [République populaire de Chine] ; Chang Liu [République populaire de Chine] ; Jiaqing Liu [République populaire de Chine] ; Guang Li [République populaire de Chine]Source :
- OncoTargets and therapy [ 1178-6930 ] ; 2020.
Abstract
In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistance will assist in exploring new immunotherapy strategies, controlling the progress of the disease, and thus bringing more sustainable survival benefits to patients. The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells. Given that PD-1/PD-L1 blockade is primarily involved in step 7, any abnormalities in the previous steps may affect the efficacy of PD-1/PD-L1 inhibitors and lead to drug resistance. This review discussed the resistance mechanisms of PD-1/PD-L1 blockade in each cancer-immunity step to finding a more suitable treatment population and an optimized combination therapy to exert immunotherapy in tumor treatment to a greater extent.
Url:
DOI: 10.2147/OTT.S239398
PubMed: 32021257
PubMed Central: 6954840
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A84
Links to Exploration step
PMC:6954840Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</title><author><name sortKey="Zhuang, Yuan" sort="Zhuang, Yuan" uniqKey="Zhuang Y" first="Yuan" last="Zhuang">Yuan Zhuang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Chang" sort="Liu, Chang" uniqKey="Liu C" first="Chang" last="Liu">Chang Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Jiaqing" sort="Liu, Jiaqing" uniqKey="Liu J" first="Jiaqing" last="Liu">Jiaqing Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Li, Guang" sort="Li, Guang" uniqKey="Li G" first="Guang" last="Li">Guang Li</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32021257</idno><idno type="pmc">6954840</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954840</idno><idno type="RBID">PMC:6954840</idno><idno type="doi">10.2147/OTT.S239398</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000A84</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A84</idno><idno type="wicri:Area/Pmc/Curation">000A84</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</title><author><name sortKey="Zhuang, Yuan" sort="Zhuang, Yuan" uniqKey="Zhuang Y" first="Yuan" last="Zhuang">Yuan Zhuang</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Chang" sort="Liu, Chang" uniqKey="Liu C" first="Chang" last="Liu">Chang Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Jiaqing" sort="Liu, Jiaqing" uniqKey="Liu J" first="Jiaqing" last="Liu">Jiaqing Liu</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Li, Guang" sort="Li, Guang" uniqKey="Li G" first="Guang" last="Li">Guang Li</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">OncoTargets and therapy</title><idno type="eISSN">1178-6930</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistance will assist in exploring new immunotherapy strategies, controlling the progress of the disease, and thus bringing more sustainable survival benefits to patients. The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells. Given that PD-1/PD-L1 blockade is primarily involved in step 7, any abnormalities in the previous steps may affect the efficacy of PD-1/PD-L1 inhibitors and lead to drug resistance. This review discussed the resistance mechanisms of PD-1/PD-L1 blockade in each cancer-immunity step to finding a more suitable treatment population and an optimized combination therapy to exert immunotherapy in tumor treatment to a greater extent.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OTT</journal-id><journal-id journal-id-type="pmc">ott</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32021257</article-id><article-id pub-id-type="pmc">6954840</article-id><article-id pub-id-type="publisher-id">239398</article-id><article-id pub-id-type="doi">10.2147/OTT.S239398</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</article-title><alt-title alt-title-type="running-authors">Zhuang et al</alt-title><alt-title alt-title-type="running-title">Zhuang et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhuang</surname><given-names>Yuan</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chang</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jiaqing</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Guang</given-names></name><xref ref-type="corresp" rid="AN0001"></xref><xref ref-type="aff" rid="AFF0001">1</xref></contrib><aff id="AFF0001"><label>1</label><institution>Department of Radiation Oncology, The First Affiliated Hospital of China Medical University</institution>,<addr-line>Shenyang</addr-line><addr-line>110001</addr-line>,<addr-line>Liaoning</addr-line>,<country>People’s Republic of China</country></aff></contrib-group><author-notes><corresp id="AN0001">Correspondence: Guang Li <institution>Department of Radiation Oncology, The First Hospital of China Medical University</institution>, <addr-line>155 North Nanjing Street, Heping District</addr-line>, <addr-line>Shenyang</addr-line>, <addr-line>Liaoning</addr-line><addr-line>110001</addr-line>, <country>People’s Republic of China</country><phone>Tel +86-13804058616</phone> Email zyyannis0701@163.com</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><fpage>83</fpage><lpage>94</lpage><history><date date-type="received"><day>20</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>© 2020 Zhuang et al.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Zhuang et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>In recent years, the PD-1/PD-L1 axis blockade has become a very promising therapy with significant clinical benefits for multiple tumor types. However, some patients still do not respond sufficiently to PD-1/PD-L1 targeted monotherapy. Therefore, investigating the mechanism of PD-1 blockade resistance will assist in exploring new immunotherapy strategies, controlling the progress of the disease, and thus bringing more sustainable survival benefits to patients. The tumor-immune cycle is divided into the following seven steps: the release of cancer antigens, cancer antigen presentation, priming and activation, trafficking of T cells to tumors, infiltration of T cells into tumors, recognition of cancer cells by T cells, and killing of cancer cells. Given that PD-1/PD-L1 blockade is primarily involved in step 7, any abnormalities in the previous steps may affect the efficacy of PD-1/PD-L1 inhibitors and lead to drug resistance. This review discussed the resistance mechanisms of PD-1/PD-L1 blockade in each cancer-immunity step to finding a more suitable treatment population and an optimized combination therapy to exert immunotherapy in tumor treatment to a greater extent.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>immunotherapy</kwd><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>resistance</kwd></kwd-group><counts><fig-count count="1"></fig-count><ref-count count="98"></ref-count><page-count count="12"></page-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000A84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:6954840
|texte= Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:32021257" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |